PhD, Iowa State University

Postdoc, California Institute of Technology

Dr. Wu served as Senior fellow/project manager at Schering-Plough with 20+ years of experience in experience in the pharmaceutical industry, with pioneering contributions in the development of new drugs for oncology, cardiovascular disease, diabetes, obesity, Alzheimer’s disease, etc.

New Jersey Minority Contribution Award, 2005

Schering-Plough research & development president’s award, 2006

National Distinguished Expert, China, 2012

Published 100+ peer-reviewed research articles

Obtained 50+ issued US/EU/Chinese patents

 

BS, University of Science and Technology of China

MS, Chinese Academy of Sciences

PhD, Iowa State University

Postdoc, Cornell University

Dr. Li previously served as R&D Chief Science Officer and project manager at Bristol-Myers Squibb, where he focused on innovative drug discovery and development. He is a seasoned scientist and entrepreneur with over 25 years of experience in the pharmaceutical industry, including expertise in target initiation/validation, PCC discovery, CMC, pre-clinical safety evaluation, IND filing, and early clinical development.

Dr. Li has discovered, led, and delivered 15 development candidates (PCCs) in diverse therapeutic areas, such as oncology, metabolic disease, aging diseases, and fibrosis. Several PCCs have entered phase I/II/III clinical trials, and he was involved in the early development of 2 FDA-approved drugs.

 

First Prize, The State Scientific and Technological Progress Award, China, 1992

Special Prize, Chinese Analytical Association, China, 1993

Molecule of the Year, Bristol-Myers Squibb, 1999/2001

Leadership Award, Bristol-Myers Squibb, 2011

Published 40+ peer-reviewed research articles

Obtained 50+ issued US/global patents, and 10+ patents pending

BS in Geodesy and Geomatics, Wuhan University

MS in Finance, Peking University

EMBA, Cheung Kong Graduate School of Business

Co-founder and Partner at Huge Capital

Mr. He has 15 years of rich experience in equity investment management and exit strategies, previously serving as a partner at JD Capital before founding Huge Capital. He has also worked for State Development and Investment Corporation and China Aviation Industry Corporation II, bringing deep industry resources and a broad network of contacts. Mr.

He has personally managed nearly 10 billion RMB and led his team to invest in star projects such as Ovctek China, Senior Technology Material Co., Ltd, Feitian Technologies Co., Ltd, Tongwei Co., Ltd., Sunwoda EVB, TYK Medicines, and Fengchao Energy Science and Technology Co., Ltd., among others. With the “Exit for Investing” strategy, he has helped LPs achieve substantial returns.

In 2022, he was honored with the “2022 Outstanding Innovative Investor TOP 50 in China” by Chines Venture, and the “2022 TOP 10 Influential Investors in Hard Technology” by LPCLUB.

 

BS in Chemistry, Fudan University

MBA, University of Washington

PhD in Organic Chemistry, University of Missouri

Currently serves as CSO at Huahai Pharmaceutical and CEO at Shanghai SynCores Technology, Inc.

Dr. Gu has extensive experience in research and development, operations, and management for contract research organizations (CROs), innovative drugs, and generic drugs. He previously served as a senior scientist at Mallinckrodt Plc, CMC vice president, and operations vice president at WuXi AppTec. He is also the founder of WuXi STA, a subsidiary of WuXi AppTec. He oversaw the sales of innovative drugs at WuXi AppTec, CMC services from phase I to III for global clients, and the commercialization of marketed products.

Dr. Gu is a professor-level senior engineer. He jointly advises at China Pharmaceutical University and Zhejiang University for the professional master, PhD, and postdoctoral programs.

Dr. Gu published 100+ peer-reviewed research articles and issued patents.

BS, Nanjing University

PhD in Molecular Biology, Penn State University

The current partner at Addor Capital

She has years of experience in research, management, and entrepreneurial investment in life sciences. Focuses on biotechnology, pharmaceutical technology, medical services, and other related areas, having led and participated in over 30 investment projects, including Huaheng Biotech (688639), Sansure Biotech (688289), Yizhong Pharma (688091), Bright Eye hospital(301239), BMC Medical Co. Ltd (301367), Dac Biotech, Shulan Health, Ab&B Biotech, TYK Medicines, Wuxi Nest Biotech, Sifary Medical Technology Co.,Ltd, More Dental, 3A Materials, Arthur Pharma, MDHC, BIODA Life Science, and Biosion, among others.

PhD in Economics, Fudan University

Postdoc in Finance, Shanghai International Group

Currently serves as Chairman of Shanghai Sun Rock Capital Management Co., Ltd. and the Investment Decision Committee of the Yangtze River Delta Industrial Innovation Fund.

He has 17 years of experience in investment and financing operations, fund establishment and management, M&A of listed and non-listed companies, financial risk management, and securities research experiences. He has directly participated in investments and exits totaling several billion yuan. He has been responsible for the establishment of Sailing Capital Management Co., Ltd, Real Power Innovative Industry Fund, Shanghai Guohe Capital, Shanghai Shipping Industry Fund, and Shanghai Healthcare Industry Investment Fund, and co-led the establishment of Real Power Innovation Fund. He has also been involved in the M&A of listed companies such as Shanghai Pudong Development Bank Co., Ltd, Shanghai AJ Group Co., Ltd, and Shanghai Industrial Development Co., Ltd.

 

The First Prize, Shanghai Financial Innovation Award, China, 2013

Golden Medal, Private Equity Fund and Capital Innovation, China, 2018

 

BS, Cambridge University

Executive-in-Residence at BioTrack Capital

Over a decade of experience in pharmaceutical industry operations and investments and have held positions such as VP at Sequoia Capital China. Have led investments in several innovative pharmaceutical companies such as Moderna (mRNA), Adagene, Virtuoso Therapeutics, and C4 Therapeutics (CCCC).

Previously participated in investment projects including BGI (300676), Betta Pharma (300558), ARMO Biosciences (acquired by Eli Lilly for $1.6 billion), GRAIL (acquired by Illumina for $8 billion), and Burning Rock Biopharma (BNR), among others.